Cross-Species Organ Transplantation Market to Grow at 8.3% CAGR from 2025-2029

The Business Research Company's Cross-Species Organ Transplantation Market to Grow at 8.3% CAGR from 2025-2029

The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, September 11, 2025 /EINPresswire.com/ -- "Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

What Is The Cross-Species Organ Transplantation Market Size And Growth?
In recent times, we have observed a robust growth in the market size of cross-species organ transplantation. The value of this market is expected to escalate from $13.98 billion in 2024 to approximately $15.20 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.7%. This noticeable growth during the historical phase has been largely spurred by animal model testing, the advent of debates on bioethics, a growing incidence of chronic diseases, experimental transplants from pigs to primates, and a high death rate resulting from final-stage organ failure.

> It will grow to $20.95 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%."
>
> *The Business Research Company*

The market of organ transplantation across species is projected to experience solid growth in the coming years, with an expected value of $20.95 billion in 2029, and an 8.3% compound annual growth rate (CAGR). Factors contributing to this anticipated growth during the forecast period include the increasing necessity for transplant organs, higher investment in regenerative medicine, worldwide chronic kidney and liver disease burden, patient campaigns for transplant accessibility, and a decline in the number of available human donors. Key trends forecasted to emerge during this period involve the production of gene-edited pig organs, genome engineering compatible with humans, the introduction of artificial intelligence in organ pairing, 3D bioprinting of vascular structures, machine perfusion and preservation technology, along with nanoscale drug delivery for immunosuppression.

Download a free sample of the cross-species organ transplantation market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27267&type=smp

What Are The Current Leading Growth Drivers For Cross-Species Organ Transplantation Market?
The uptick in genetic engineering practices is anticipated to spur the expansion of the cross-species organ transplantation market. Genetic engineering concerns the intentional alteration of an organism's genes via biotechnology techniques to add, delete, or change specific genes. The escalation in genetic engineering is fueled by the immediate necessity to overcome organ scarcities by creating animal organs that are more suited for human transplantation. Genetic engineering bolsters the development of cross-species organ transplantation by facilitating the modification of animal organs to decrease immune rejection, thus making them ideal for human transplants. To exemplify, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit scientific and medical organization, reported that there were 247 gene therapies in Phase II by the end of the first quarter of 2023, escalating by 5% to reach 260 by the end of the second quarter. Consequently, the increasing pivot towards genetic engineering is catalyzing the advancement of the cross-species organ transplantation market.

Which Companies Are Currently Leading In The Cross-Species Organ Transplantation Market?
Major players in the Cross-Species Organ Transplantation Global Market Report 2025 include:
• Pfizer Inc
• F. Hoffmann-la Roche Ltd
• Sanofi SA
• Novartis AG
• Optipharm Co Ltd
• Astellas Pharma Inc.
• United Therapeutics Corporation
• TransMedics Group Inc.
• Artivion Inc.
• eGenesis Inc.

What Are The Key Trends And Market Opportunities In The Cross-Species Organ Transplantation Sector?
Leading firms in the cross-species organ transplantation market are prioritizing the establishment of strategic partnerships to ease the regulatory approval process for xenotransplantation solutions. Such partnerships are alliances that bring companies together to leverage each other's expertise and resources, with the shared aim of stimulating expansion, innovation, and competitiveness without amalgamation. For example, in February 2025, United Therapeutics, a biotechnology company based in the US, joined forces with eGenesis, a US-based pharmaceutical enterprise, to initiate clinical trials for the transplantation of pig kidneys (xenotransplant) into humans. The U.S. Food and Drug Administration (FDA) approved this trial, which seeks to transplant genetically altered pig kidneys into patients suffering from kidney failure. The primary objective of these trials is to find a solution to the severe shortage of donor

kidneys by potentially offering a new, sustainable source of organs for those in need.

How Is The Cross-Species Organ Transplantation Market Segmented?
The cross-species organ transplantation market covered in this report is segmented

1) By Product Type: Organ Preservation Solution, Transplant Diagnostics, Xeno Products, Other Product Types
2) By Application: Kidney, Heart, Liver, Lung, Other Applications
3) By End-User: Transplant Centers, Hospitals, Other End-Users

Subsegments:
1) By Organ Preservation Solution: Hypothermic Machine Perfusion (HMP) Solutions, Normothermic Machine Perfusion (NMP) Solutions, Static Cold Storage (SCS) Solutions, Oxygenated Perfusion Solutions
2) By Transplant Diagnostics: Histocompatibility Testing, Crossmatching Tests, Molecular Typing (DNA-based Testing), Immunological Monitoring Assays
3) By Xeno Products: Genetically Engineered Donor Organs, Decellularized Organ Scaffolds, Xenogeneic Cellular Therapies, Immunosuppressive Regimens For Xenotransplants
4) By Other Product Types: Organ Transport Devices, Organ Recovery and Preservation Equipment, Surgical Instruments For Transplantation, Post-Transplant Monitoring Devices

View the full cross-species organ transplantation market report:
https://www.thebusinessresearchcompany.com/report/cross-species-organ-transplantation-global-market-report

Which Is The Dominating Region For The Cross-Species Organ Transplantation Market?
In 2024, the biggest regional market for cross-species organ transplantation was North America. However, the fastest-growing region projected for the forecast period is Asia-Pacific. This report covers the following markets: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Cross-Species Organ Transplantation Market 2025, By The Business Research Company

Landscaping Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/landscaping-services-global-market-report

Crop Production Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

Courier Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/courier-services-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/847670597

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2025 Newsmatics Inc. All Right Reserved.